Skip to main content
Fig. 1 | Trials

Fig. 1

From: A pragmatic randomized controlled trial to evaluate the efficacy and safety of an oral short-course regimen including bedaquiline for the treatment of patients with multidrug-resistant tuberculosis in China: study protocol for PROSPECT

Fig. 1

Schematic overview of the study design. BDQ, bedaquiline; CFZ, clofazimine; CS, cycloserine; LFX, levofloxacin; LZD, linezolid; PTO, prothionamide; PZA, pyrazinamide. aIf a participant is still sputum culture-positive for Mycobacterium tuberculosis by week 16, BDQ treatment will be extended from 24 to 40 weeks

Back to article page

Trials

ISSN: 1745-6215